Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Sarcoma 17Glioblastoma 10Brain Neoplasms 10Gliosarcoma 9Rhabdomyosarcoma 7Osteosarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Sarcoma, Ewing 5Recurrence 5Leukemia, Myeloid, Acute 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Astrocytoma 5Oligodendroglioma 4Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Hodgkin Disease 4Glioma 4Rhabdoid Tumor 3Primary Myelofibrosis 3Neurofibrosarcoma 3Neuroblastoma 3

Interventions

AZD 6244 3X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1Sirolimus 1Radiotherapy 1Photons 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1Ifosfamide 1High-Energy Shock Waves 1Filgrastim 1Etoposide 1Doxorubicin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Sirolimus × Sarcoma × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡